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Summary
Synovial sarcoma is a highly aggressive soft tissue malig-
nancy that often affects adolescents and young adults. It is
associated with a unique chromosomal translocation that
results in the formation and expression of the fusion gene
SS18-SSX, which underlies its pathogenesis. Although
SS18-SSX provides a potentially unique therapeutic tar-
get, all attempts to neutralise it have been unsuccess-
ful thus far. When complete surgical removal of the tu-
mour fails, therapy is limited to largely ineffective cytotoxic
drug regimens. Nevertheless, recent discoveries about the
mechanisms of SS18-SSX protein function have provid-
ed insight into potential alternative therapeutic strategies.
SS18-SSX displays oncogenic activity through protein-
protein interactions and participation in chromatin remod-
elling complexes. This review summarises our current un-
derstanding of the function of SS18-SSX and the
mechanisms by which it alters the epigenetic landscape of
permissive cells to induce transformation and the subse-
quent development of synovial sarcoma.
Keywords: synovial sarcoma, SS18-SSX, chromatin, epi-
genetics, pathogenesis
Introduction
Synovial sarcoma accounts for 10 to 20% of all soft tissue
sarcomas in the adolescent and young adult population
and is the most common soft tissue sarcoma after rhab-
domyosarcoma [1]. Its salient biological feature is the non-
random chromosomal translocation t(X:18; p11:q11),
which generates fusion between the nearly entire coding
sequence of the SS18 gene and a portion of the coding se-
quence of an SSX gene (SSX1 and SSX2 being the two most
commonly implicated). Similarly to numerous paediatric
malignancies, synovial sarcoma is genetically quiescent
and typically displays few genetic mutations other than
the chromosomal translocation. Transformation of prima-
ry cells and subsequent tumour development are therefore
driven by SS18-SSX, which functions as a regulator of
gene expression despite lacking DNA-binding motifs.
SS18-SSX interacts with numerous proteins, several of
which play a central role in the regulation of the cellular
epigenetic status and cumulating evidence suggests that
most of the oncogenic properties of SS18-SSX stem from
its ability to orchestrate epigenetic changes in the affected
cells.
Incidence and clinical features
Although it occurs most frequently in young individuals,
with a median age of 35 years, synovial sarcoma afflicts
patients from 5 to more than 80 years of age [2]. A recent
study on synovial sarcoma incidence and survival in the
USA covering three decades (from 1983 to 2012) revealed
that the incidence per 1,000,000 increased from 0.9 to 1.5
in the total population within this time span and peaked
within the 15 to 29 age range, reaching 2.2 per 1,000,000
in the third decade of the study [3]. The same study found
that 5-year survival rates of synovial sarcoma did not im-
prove over the three decades and in fact decreased from
69.4% between 1983 and 1992 to 60.1% between 2003 and
2012 [3]. Although these observations may at least in part
reflect an increase in diagnostic accuracy, they neverthe-
less underscore the need to elucidate the pathogenesis of
synovial sarcoma and develop effective, mechanism-based
therapeutic strategies. There are no data as to the precise
incidence of synovial sarcoma in Switzerland, but based on
the number of new cases each year in university hospitals,
the incidence can be estimated to be comparable to that in
the USA.
Synovial sarcoma was first reported in 1865 [1] and de-
scribed as a tumour proximal to a joint with a histological
resemblance to developing synovium, leading to its label.
Later immunohistochemical and ultrastructural analyses
refuted the notion that the tumour bears synovial features
[4], but the label has remained despite the widely held view
that it is a misnomer. Consistent with this notion are re-
ports that synovial sarcoma can arise in tissues unrelated to
joints including the lung [5], digestive tract [6], bone mar-
row [7], kidney [8] and heart [9].
About 75% of synovial sarcomas arise in the extremities,
predominantly in the lower limbs [10–12]. Clinical signs
are non-specific, the tumour most commonly appearing as
a slowly growing, palpable, tender mass, whose radiologi-
cal features resemble an oval, soft tissue opacity associat-
ed with calcifications in about 25% of cases [13]. On mag-
netic resonance imaging (MRI), synovial sarcoma displays
an image that has been described as the triple signal pat-
tern, which reflects a combination of calcifications, cystic
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changes due to necrosis and haemorrhage, and air fluid lev-
els [12, 13].
Synovial sarcoma falls into the category of high-grade tu-
mours based on its propensity for local invasion and high
metastatic proclivity [10, 14]. Roughly 50% of adult pa-
tients have metastatic disease at diagnosis, the lung being
the most common metastatic site [10, 15, 16]. In contrast,
only 5 to 11% of paediatric synovial sarcomas are associ-
ated with metastasis at diagnosis [10, 16]. Metastatic tu-
mours in both adults and children have complex chromo-
somal aberrations. Current therapy is the same for both
local and metastatic synovial sarcoma and consists of mul-
tiple cycles of adjuvant or neoadjuvant chemotherapy and
wide surgical resection, as well as removal of metastatic
tumours if present as a single or a few well-defined and ac-
cessible lesions. Surgical excision may be followed by ad-
juvant or neo-adjuvant radiation therapy [17]. Sensitivity
to cytotoxic drugs is relatively modest and, despite seem-
ingly complete surgical removal of local disease, early and
late recurrences are common [10]. Late local recurrences
and pulmonary metastases more than 5 years after initial
diagnosis are more typical of synovial sarcoma than other
sarcomas [15] and the current 10-year disease-free survival
following excision of local disease is about 50% [10].
Histopathology
Synovial sarcoma has the unusual property among soft tis-
sue tumours of displaying epithelial differentiation. There
are two major synovial sarcoma subtypes: the monophasic
subtype, which comprises about 75% of tumours, is com-
posed of spindle cells without any detectable epithelial fea-
tures. The biphasic subtype, which comprises the remain-
ing 25% of tumours and is composed of spindle cells as
well as cells with epithelial features, which often form
glandular structures (fig. 1). The monophasic subtype can
display poor differentiation and resemble small round blue
cell tumours, which include Ewing sarcoma, alveolar rhab-
domyosarcoma and lymphoma [18]. Most tumours express
CD99 and endothelial growth factor receptor (EGFR) [19,
20] as well as platelet-derived growth factor receptor-alpha
(PDGFRα) [21], whereas c-Met expression is associated
with particularly aggressive SS phenotypes [22, 23]. How-
ever, there are currently no specific immunohistochemical
synovial sarcoma markers and the only diagnostic molecu-
lar feature is the chromosomal translocation t(X:18).
The t(X:18) translocation – the diagnostic fea-
ture and pathogenic hallmark of synovial sar-
coma
The balanced chromosomal translocation t(X:18; p11:q11),
which is observed in virtually all cases, is unique to syn-
ovial sarcoma and is not associated with any other human
tumour. The translocation generates an in-frame fusion of
the SS18 gene (formerly referred to as SYT) to SSX1 or
SSX2 (or SSX4 in a small fraction of cases [24, 25]), in
which sequences encoding all but the 8 carboxy terminal
(C-terminal) amino acids of SS18 become fused to se-
quences encoding the C-terminal 78 amino acids of the
SSX partner. At least two observations support the notion
that SS18-SSX is the key genetic driver in synovial sar-
coma: first, it reflects the only cytogenetic abnormality in
as many as a third of cases [26, 27]; second, in condi-
tional mouse models, SS18-SSX alone can induce tumours
with histological features and a gene expression profile
reminiscent of those of human synovial sarcoma [28]. It
has been suggested that synovial sarcoma cell viability de-
creases upon SS18-SSX depletion [29], but there is sub-
stantial variability among available synovial sarcoma cell
lines, some of which remain viable and continue to prolif-
erate following SS18-SSX removal.
Cell of origin and models of synovial sarcoma
As is the case with most sarcomas, the cell of origin of
synovial sarcoma has not been easy to identify. A trans-
genic mouse model of synovial sarcoma was generated by
Figure 1: Histology of synovial sarcoma. Top: biphasic synovial
sarcoma displaying glandular structures (arrowheads); middle:
monophasic synovial sarcoma composed predominantly of dense-
ly packed spindle cells; bottom: poorly differentiated synovial sar-
coma composed of round cells with scant cytoplasm that falls into
the morphologic category of small round blue cell tumours.
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expression of human SS18-SSX in an early myoblast pop-
ulation bearing the Myf5 marker, which was unexpected
as neither human nor mouse synovial sarcomas express
muscle differentiation markers [28]. Tumours arose with
100% penetrance and displayed a phenotype reminiscent
of monophasic synovial sarcoma. The path toward devel-
oping the transgenic model suggested a narrow window
of permissiveness for SS18-SSX-mediated transformation,
as SS18-SSX expression in later stage Myf6+ myoblasts
caused myopathy but no tumours, whereas conditional ex-
pression in earlier myoblast populations (Pax3+ or Pax7+)
was embryonic lethal [30]. Embryonic lethality was also
observed upon SS18-SSX expression in bone, endothelial
and neural precursor populations as well as in early ec-
toderm [30]. Somewhat surprisingly, tamoxifen-induced
conditional expression of SS18-SSX resulted in the devel-
opment of more indolent tumours in atypical anatomical
locations, including facial and paraspinal sites, suggesting
that cells other than Myf5+ myoblasts may be permissive
for SS18-SSX-mediated transformation. Consistent with
this notion, a mouse embryonic cell line, C3H10T1/2,
which displays mesenchymal stem cell (MSC) features,
was observed not only to be permissive for SS18-SSX
expression but also to acquire a gene expression profile
with significant resemblance to that of primary human syn-
ovial sarcoma [31]. The argument that a MSC subpopu-
lation may harbour the cell of origin of synovial sarco-
ma has been strengthened by the observation that silencing
of SS18-SSX in two synovial sarcoma cell lines caused
them to transit from growth in suspension, as spheres, to
growth as adherent monolayers, adopt a spindle cell phe-
notype, express mesenchymal markers and display a broad
differentiation potential to osteocytes, chondrocytes and
adipocytes [32].
SS18-SSX can be expressed in many primary human cells
without inducing senescence or apoptosis and primary hu-
man MSCs display gene expression profiles in response to
SS18-SSX expression that overlap with the synovial sar-
coma transcriptome [33]. However, the response was di-
vergent among different batches of MSCs, some of which
upregulated numerous genes associated with synovial sar-
coma, whereas others displayed only minimal transcrip-
tome changes despite allowing SS18-SSX protein expres-
sion. These observations support the notion that SS18-SSX
may have a narrow window of opportunity to exert its
oncogenic functions in primary cells, which is determined
by host cell properties, most likely including their differen-
tiation state. MSCs are defined by the expression of a set of
common cell surface markers, the lack of lineage-specif-
ic markers, and the ability to differentiate along a variety
of mesenchymal lineages under appropriate culture con-
ditions [34]. However, these cells are heterogeneous such
that any bulk MSC population may harbour subpopulations
at discrete stages of differentiation, whose permissiveness
for defined oncogenic events may differ markedly. It is
therefore likely that permissiveness for oncogenic fusion
protein expression, be it SS18-SSX or a fusion protein that
underlies the pathogenesis of other sarcomas [35, 36], is
the property of only some of these putative subpopulations.
Currently, the lack of selective markers for discrete stages
of MSC differentiation is a limitation in MSC biology in
general and in determining the origin of a variety of sarco-
mas in particular. Furthermore, bone marrow and periph-
eral tissue MSCs display the same markers but differ in
their expression of a variety of mediators [37] and neural
crest derived MSCs display different features still. It will
be highly instructive to determine the composition of MSC
populations from different anatomical sites and how they
respond to diverse sarcoma-specific oncogenic events.
Similar to other solid tumours, synovial sarcomas display
intratumour heterogeneity. Although the observed hetero-
geneity appears to arise according to the cancer stem cell
(CSC) model, synovial sarcoma CSCs remain to be char-
acterised. Primary synovial sarcoma cells grow in suspen-
sion as spheres in serum-depleted medium and low attach-
ment plates. The spheres are enriched in cells expressing
stem cells markers Oct3/4, Nanog and Sox2 and some can
initiate tumour growth in serial transplantation assays [32],
which is consistent with enrichment in CSCs. However,
with few exceptions [38], these cells do not express mark-
ers that are commonly associated with, although not spe-
cific for, CSCs. Although expression of the chemokine re-
ceptor CXCR4 has recently been reported to be associated
with tumour-initiating properties in synovial sarcoma cells
[39], the observation was made in cell lines, which may
deviate phenotypically from primary cells endowed with
self-renewal and tumour-initiating properties. The putative
cell hierarchy in synovial sarcoma will therefore have to be
addressed using alternative approaches in primary tumour
cells, such as reporter systems based on the expression of
stem cell-associated transcription factors and repression of
differentiation-inducing factors, including key microRNAs
(miRNAs).
SS18 and SSX proteins
Although a fusion protein typically displays unique fea-
tures, including oncogenic properties, which its wt com-
ponent proteins may lack, the physiological properties of
each of its constituent proteins should at least partially ex-
plain its functions. The SS18-SSX fusion protein is a case
in point.
SS18 and its implication in the BAF complex
SS18 encodes a 387 amino acid protein that is ubiquitously
expressed in normal tissues from embryogenesis [40] to
adulthood [24] and whose deletion causes early embryonic
lethality. Although its physiological function remains to be
fully elucidated, SS18 is implicated in chromatin modifi-
cations and in the regulation of gene expression. The wild
type SS18 protein can be subdivided into three function-
al regions: an N-terminal 54 amino acid SYT N-termi-
nal homology domain (SNH domain); a domain containing
the nuclear localisation sequence; and the carboxy termi-
nal (C-terminal) transcriptional activation region known as
the QPGY domain (fig. 2). SS18 is observed in the cy-
toplasm but also forms unique nuclear bodies that appear
as distinct nuclear speckles [41]. SS18 does not contain a
DNA-binding domain and appears to regulate transcription
by associating with proteins that form part of the SWI/SNF
(SWItch/sucrose non-fermenting) or BAF (Brg/Brm-asso-
ciated factor) chromatin remodelling complex, including
BRG1 (Brahma-related gene 1 or SMARCA4) and BRM
(human Brahma, or SMARCA2) [42–44].
Chromatin is the macromolecular complex of DNA and hi-
stone proteins in which the heritable material of eukaryotic
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cells is stored. Its basic functional unit is the nucleosome,
which contains 147 bases of DNA wrapped around a sin-
gle octamer of histone proteins [45, 46]. Whereas the sta-
bility of the nucleosomal structure safeguards the genome,
temporal and spatial DNA accessibility requires dynamic
changes to the nucleosome architecture. Such changes are
orchestrated by a variety of chromatin remodelling com-
plexes, which modify histones to induce nucleosomal al-
terations [45]. Chromatin remodelling complexes are com-
posed of multiple protein subunits at the core of which
is an ATPase, which hydrolyses ATP to alter nucleosomal
structures. The additional subunits fulfill specialised roles
required for the function of the complex. The remodelling
activity regulates binding of transcription factors to func-
tional DNA elements, including promoters and enhancers.
Chromatin relaxation, induced by activating histone mod-
ifications often referred to as “marks”, augments DNA
accessibility to transcription factors, facilitating gene ex-
pression. Conversely, chromatin compaction triggered by
repressive histone marks, renders DNA inaccessible to
transcription factors and results in gene silencing [45].
BAF complexes mobilise nucleosomes on genomic DNA
[47] to create nucleosome-depleted regions at core pro-
moters distal regulatory elements and render DNA acces-
sible to transcription factors. BAF activity drives changes
in chromatin states across the genome and is associated
with the activation of a broad range of transcription pro-
grammes, including stemness maintenance and differentia-
tion [48, 49]. The mammalian BAF chromatin remodelling
complex comprises 15 protein subunits and interacts with
a range of nuclear proteins that help target the complex to
specific regulatory elements where they can further recruit
factors that regulate gene expression. SS18 has been found
to be an integral component of the BAF complex [44] and
to interact with several of its subunits [50].
SS18 binds to hBRM and BRG1, two mutually exclusive
catalytic ATPase subunits of BAF [51] at a conserved re-
gion known as the SNF11-binding domain [43, 52] and
associates with hSNF5/BAF47 [53]. SS18 interacts with
mSin3A (mammalian switch-independent 3A) [54], a core
component of the histone deacetylase (HDAC) complex
[55], which is associated with BAF [56] and affects chro-
matin through co-repressors and methyl-CpG-binding pro-
teins resulting in repression of gene transcription [57]. A
region within the N-terminal 250 amino acids of SS18
recognises the histone acetyltransferase p300, whose activ-
ity relaxes chromatin, thereby acting as a transcriptional
coactivator [58, 59]. One effect of the SS18/p300 complex
is to activate β1 integrin and promote adhesion of cells that
have undergone cell cycle arrest by contact inhibition [60].
All of these interactions are supported by the SNH do-
main and/or the nuclear localisation signal-containing do-
main (fig. 2).
The QPGY domain of SS18 contains a 100 amino acid
sequence composed of degenerate repeats of glutamine,
proline, glycine and tyrosine residues that mediates mul-
timerisation of the SS18 protein [52]. It interacts with
SS18-interacting protein / co-activator activator protein
(SIP/CoAA) [61], which associates with p300 and several
hormone response elements [62].
SSX proteins and gene repression
Nine members compose the SSX gene family and encode
188 amino acid proteins, with the exception of SSX8,
which encodes a smaller, 142 amino acid protein [63].
Roughly 40% of each SSX protein is composed of charged
amino acids and each SSX protein contains an acidic car-
boxy terminal tail with consensus motifs for posttrans-
lational modifications, including tyrosine phosphorylation
and N-linked glycosylation [64]. SSX contains two prin-
cipal functional domains: KRAB (Krüppel-associated box)
and SSXRD (SSX repression domain) [65]. A third do-
main of unknown function, located immediately upstream
of SSXRD, displays the highest degree of divergence
among SSX family members and is referred to as the SSX
divergent domain (SSXDD) [66] (fig. 2). Unlike the broad
distribution of SS18, SSX in normal adult tissues is con-
fined to the testis and the thyroid, albeit at very low levels
in the latter [63, 64]. In contrast, SSX is expressed in diver-
gent tumour types, including breast carcinoma, osteosarco-
ma, melanoma and multiple myeloma [67–71], where its
functional role remains to be elucidated.
The SSX proteins are potent transcriptional repressors. Re-
pression is mediated both by the KRAB domain and by
the SSX repressor domain (SSXRD), which is highly con-
Figure 2: The SS18-SSX fusion protein. Illustration of the domain structure of SS18 and SSX and the regions within each that support inter-
action with the indicated proteins. The grey encasing indicates the segments of each partner that form part of the fusion protein (below). The
indicated fusion partner domains are: SNH, SS18 N-terminal homology; QPGY, glutamine-proline-glycine-tyrosine-rich domain; KRAB, Krup-
pel-associated box domain; DD, divergent domain; RD, repression domain; NLS, nuclear localisation signal.
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served among SSX1-5 proteins and is responsible for SSX
nuclear localisation. In the nucleus, SSX co-localises with
several members of the polycomb group proteins, includ-
ing human polycomb group protein 2 (HPC2), B cell-spe-
cific moloney murine leukaemia virus insertion site 1 pro-
tein (BMI1) and ring finger proteins 1 and 2 (RING1 and
RING2) [71]. PcG proteins form two multiprotein com-
plexes, polycomb repressive complex 1 and 2 (PRC1 and
PRC2), which respectively direct histone HA2 ubiquitina-
tion (H2AK119ub1) and trimethylation of histone H3 at
lysine 27 (H3K27me3), leading to chromatin compaction
that renders regulatory regions inaccessible to RNA poly-
merase II [72–74]. It appears that intact SSX is required for
the recruitment of BMI1, as its amino-terminal domain is
necessary for BMI1 interaction [75].
Known interactors of SSX proteins include RAB3IP, a
Ras-like GTPase, which participates in vesicular transport
and synovial sarcoma X-breakpoint 2 interacting protein
(SSX2IP), which is implicated in cell cycle regulation [76].
Both proteins recognise the KRAB domain of SSX but the
RAB3IP interaction is restricted to SSX2, whereas SSX2IP
binds SSX2 and SSX3, suggesting selectivity among SSX
family members for functional partners [76]. The carboxy
termini of SSX1, SSX2 and SSX4 interact with LIM home-
obox protein 4 (LHX4) which displays transcription factor
features [65] and whose expression appears to be deregu-
lated in acute and chronic leukaemias, possibly promoting
leukaemia cell survival [77].
The SS18-SSX fusion protein
The SS18-SSX fusion protein is unique to synovial sarco-
ma and is both its signature feature and the driver of its
pathogenesis. The fusion protein retains all of the SS18
protein with the exception of carboxy-terminal eight amino
acids, which is fused to the highly polar carboxy-terminal
SSX region. Whereas the SSXDD and SSXRD domains
are preserved in the fusion protein, the KRAB DNA-bind-
ing domain is lost along with its binding partners, allowing
novel protein-protein interactions. Thus, the fusion protein
interacts with the epithelial-to-mesenchymal transition-in-
ducing transcription factors Snail and Slug, resulting in
partial alleviation of E-cadherin repression [78]. Retention
of the carboxy-termini of SSX1, SSX2 and SSX4 in the fu-
sion proteins ensures their interaction in vivo with proteins
recognised by their wt counterparts [77].
Chromatin remodelling associated with
SS18-SSX
Similar to wt SS18, SS18-SSX co-precipitates and co-sed-
iments with hBRM and BRG1 of the BAF chromatin re-
modelling complex and HDAC [31, 43, 79]. SS18-SSX
has been suggested to replace wt SS18 in the BAF complex
and alter its composition by ejecting the tumour suppressor
hSNF5/BAF47 [53] (Figure 3). Interestingly, wt SS18 can
in turn replace the SS18-SSX fusion protein, suggesting
that the two proteins may compete for incorporation into
BAF complexes. SS18-SSX also retains some of the PcG
binding properties of SSX and localises at discrete nuclear
foci within BMI-labelled polycomb bodies [80]. The
SS18-SSX fusion protein therefore employs two distinct
domains to associate with chromatin remodelling com-
plexes that display opposing functions.
In normal cells, the PRC2 methyltransferase enhancer of
zeste homologue 2 (EZH2) induces trimethylation of his-
tone H3, leading to chromatin compaction [72, 74]. Chro-
matin immunoprecipitation sequencing (ChIP-seq) results
from tagged SS18-SSX expressed in C2C12 mouse my-
oblasts uncovered a relationship between SS18-SSX bind-
Figure 3: Relationship between SS18, SS18-SSX and the BAF complex. SS18 is an integral part of the wt BAF complex (left). The
SS18-SSX fusion protein displaces wt SS18 and BAF47 within the complex (right).
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ing and repressive trimethylated histone H3K27 nucleo-
some marks [81]. SS18-SSX2 was reported to occupy
H3K27me3 labelled regions within 70% of positively reg-
ulated and 40% of negatively regulated genes in these
cells. The association of SS18-SSX2 with H3K27me3
marks suggests that the fusion protein does not randomly
target to regions of open chromatin but rather occupies a
subset of PcG loci [81]. It has also been suggested that
H3K27me3 motifs represent one of the dominant epige-
netic markers associated with SS18-SSX binding and gene
repression [82] and that elevated EZH2 expression is ob-
served in poorly differentiated synovial sarcomas where it
correlates clinically with a worse outcome [83].
However, the role of PRC-dependent marks in synovial
sarcoma pathogenesis remains to be determined in view of
the notion that the BAF complex antagonises its PcG coun-
terparts. Several mechanisms have been proposed to un-
derlie the functional opposition of BAF toward PcG. BAF
directly recruits RNA PolII, thereby opposing PcG com-
plexes that interact with RNA PolII complexes to promote
transcriptional elongation [84, 85]. Loss of hSNF5/BAF47
is reported to cause augmented expression of EZH2 [85],
suggesting that the antagonistic action of BAF toward PcG
requires that hSNF5/BAF47 counteract EZH2 activity by
downregulating its expression. More recent observations
suggest that BAF can rapidly evict PRCs in the absence
of RNA PolII occupancy, transcription and cell replication
[86] and propose that BAF complexes fulfill instructive
functions by preparing PcG-repressed loci for accessibility
to transcription factors (fig. 4). Thus, the SS18-SSX-mod-
ified BAF complex is reported to be recruited to the in-
active SOX2 locus where it reverses PcG-mediated repres-
sion by removing Polycomb resulting in the activation of
the transcription factor SOX2, which is highly expressed
in synovial sarcoma and contributes to the proliferation
of synovial sarcoma cells [32, 53]. The modified BAF
complex activity may therefore promote oncogenesis by a
combination of imbalanced PRC activity and aberrant epi-
genetic activation of PcG targets, which may lead to onco-
gene activation, tumour suppressor gene repression and in-
duction of stem cell-associated programmes [85].
Signalling pathways and transcription factors
in synovial sarcoma pathogenesis
At least two possible non-mutually exclusive mechanisms
may underlie SS18-SSX/BAF-mediated induction of
SOX2 and other target genes. One may be recruitment of
the complex to DNA by a pioneer transcription factor that
activates regulatory regions, including the creation of de
novo enhancers; the other may be relatively nonspecific at-
tachment of the complex to DNA, resulting in broad chro-
matin relaxation and accessibility of regulatory regions to a
wide range of transcription factors devoid of pioneer func-
tion [86]. Transcription factors that may recruit SS18-SSX
to DNA promoter or enhancer regions have largely re-
mained elusive. However, recent work has identified two
distinct sets of transcription factors that may fulfill the
function of recruiting SS18-SSX to promoter and enhancer
regions of candidate target genes. Thus, SS18-SSX has
been proposed to serve as a scaffold that bridges activating
transcription factor 2 (ATF2) and transducing-like en-
hancer of split 1 (TLE1). ATF2 binds to the SNH domain
of SS18 whereas TLE1 is recruited to SSXRD [87].
SS18-SSX is suggested to be recruited to target promoters
of ATF2, where the repressor activity of TLE1 causes
ATF2 target gene silencing [87].
Potential recruitment of SS18-SSX to DNA may also be
effected by transcription factors of the Wnt pathway, which
is suggested to be implicated in synovial sarcoma patho-
genesis [88–90]. The Wnt family of secreted proteins ful-
fills key evolutionarily conserved functions in normal de-
velopment and adult tissue maintenance [91–93] and its
deregulation by alteration of expression or mutation of its
key components including β-catenin, Adenomateous Poly-
posis Coli (APC) and AXIN, is associated with develop-
ment and progression of diverse cancer types [93–96].
Expression of SS18/SSX in HEK293 cells has been sug-
gested to activate Wnt- β-catenin signalling. Studies on
the MYF5-CRE SS18/SSX2 transgenic model of synovial
sarcoma found that SS18-SSX2 aberrantly activates Wnt/
β-catenin signaling and that genetic deletion of β-catenin
blocks tumour formation [97]. They also suggested that
SS18-SSX causes nuclear β-catenin accumulation, possi-
bly by inducing autocrine signalling through its aberrant
transcriptional effects. In contrast, introduction of
SS18-SSX into NIH3T3 cells induced Wnt ligand-inde-
pendent accumulation of β-catenin in the nucleus [88],
suggesting an alternative mechanism of SS18-SSX-depen-
dent deregulation of Wnt. Despite elevated expression of
several Wnt target genes, particularly AXIN2, increased
nuclear localisation of β-catenin is seen in only 30 to 60%
of synovial sarcomas [98–101] and genetic screens [100,
102] revealed low incidence of β-catenin, APC, AXIN1
and AXIN2 mutations [103]. The molecular mechanisms
whereby SS18-SSX may alter Wnt signalling and target
gene expression thus remain to be fully elucidated.
Recent work has shown that SS18-SSX may interact with
and even hijack the Wnt pathway in C3H10T1/2 cells [31].
One of the most highly upregulated genes in synovial sar-
coma is AXIN2, which is also one of the most context-
independent targets of Wnt. Expression of SS18-SSX in
C3H10T1/2 cells induced robust AXIN2 expression con-
sistent with activation of the Wnt pathway. Surprisingly,
whereas SS18-SSX was found to interact with Tcf4/Lef,
the core Wnt transcription factors, it did not recruit β-
catenin to the complex but rather appeared to exclude and
replace β-catenin. SS18-SSX also recruited HDAC and
TLE to the complex, potentially inactivating both [31].
Tcf4/Lef may constitute important transcription factors
that help recruit SS18-SSX to relevant promoters and pos-
sibly enhancers. Alternatively, SS18-SSX in association
with BAF may help open chromatin and allow recruitment
of Tcf/Lef to promoter and enhancers that in its absence
may be inaccessible. In either case, however, SS18-SSX
interacts with the transcription factors, possibly regulating
their activity in the absence of β-catenin.
Epithelial differentiation in synovial sarcoma
An intriguing observation in synovial sarcoma is that the
tumour phenotype (monophasic versus biphasic histology)
correlates with the underlying gene fusion type [104].
Thus, almost all biphasic synovial sarcomas have been
found to express the SS18-SSX1 fusion [104, 105]. Bipha-
sic histology occurs in 30 to 40% of tumours with
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SS18-SSX1 and only about 3% of synovial sarcomas bear-
ing SS18-SSX2 [2].
Functional differences between SS18-SSX1 and
SS18-SSX2 are thought to account for the distinct differ-
entiation profiles among tumours bearing these fusions. E-
cadherin expression is observed in a subset of synovial
sarcomas and can even be heterogeneous in the same tu-
mour, as can cytokeratin expression. SS18-SSX1 and
SS18-SSX2 can interfere selectively with Snail and Slug,
respectively, and release repression of E-cadherin expres-
sion [78]. SS18-SSX1 interacts with Snail, which is a
stronger repressor of E-cadherin than Slug, and dissociates
Snail from the E-cadherin promoter, resulting in stronger
de-repression of E-cadherin transcription [78]. This
process also implicates hyperacetylation of histones H3
and H4 induced by SS18-SSX, dissociating Snail form the
E-cadherin promoter.
A potentially interesting model has been proposed accord-
ing to which the apparent mesenchymal to epithelial tran-
sition (MET) in synovial sarcoma may be better viewed
as an EMT based on the notion that all synovial sarcoma
progenitor cells with the chromosomal translocation
t(X;18)(p11.2;q11.2) are theoretically capable of some ep-
ithelial differentiation. However, the majority of the cells
lose such capability as a result of a variety of signals [106,
107], including extracellular matrix (ECM) remodelling
[108].
Future perspectives
Elucidation of synovial sarcoma pathogenesis is confront-
ed by several major obstacles. First, the cell of origin re-
mains unknown. Although it is widely believed that syn-
ovial sarcoma arises in mesenchymal stem cells, MSCs
are heterogeneous and discrete degrees of differentiation
may suffice to render them permissive or prohibitive for
SS18-SSX expression and function. Expression of
SS18-SSX in human MSCs derived from different healthy
donors had markedly different effects in terms of target
gene expression despite cell purification and maintenance
in culture by identical methods [33]. A mouse MSC,
Figure 4: Polycomb repressor complexes induce chromatin compaction (upper panel); the BAF/SS18-SSX complex evicts PRC1/PRC2 caus-
ing displacement or decay of their marks and inducing chromatin relaxation (lower panel).
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C3H10T1/2, has shown to be permissive for SS18-SSX
expression and to upregulate numerous SS18-SSX target
genes, particularly Wnt pathway genes, recapitulating, at
least in part, the synovial sarcoma gene signature [31].
However, primary human MSCs have yet to show a com-
parable level of response to SS18-SSX expression and the
epithelial differentiation observed in about a third of syn-
ovial sarcomas raises the possibility that the cell of origin
may display greater plasticity than most MSCs as current-
ly defined. One hope is that single cell RNA sequencing of
MSCs from different anatomical sites and age groups may
uncover hitherto unsuspected markers for different subsets
and facilitate division of bulk MSCs into subpopulations
that can be tested separately for their permissiveness and
response to SS18-SSX.
The second major obstacle is the lack of SS18-SSX-spe-
cific antibodies that can be used to assess SS18-SSX com-
plexes and epigenetic changes by ChIP-seq. Currently, all
available antibodies recognise both wt SS18 and the fusion
protein. Although tagged SS18-SSX has been used to con-
duct ChIP-seq experiments, the approach has two major
limitations. First, it relies on SS18-SSX overexpression,
which may fail to recapitulate naturally occurring fusion
protein expression levels. Second, the overexpression is
typically conducted in heterologous cells whose response
to SS18-SSX may only partially mimic that of synovial
sarcoma cells of origin. One solution would be to genom-
ically tag endogenous SS18-SSX in primary synovial sar-
coma cells and to subsequently conduct ChIP-seq stud-
ies. However, even such an approach may provide only a
snapshot of a process that has evolved over time and that
may not provide an explanation as to how the image ob-
tained came to be. In other words, the mechanism that gov-
ern the antagonism between the SS18-SSX-modified BAF
complex and PcG, which is thought to be at the heart of
the epigenetic modifications that characterise synovial sar-
coma and underlie its pathogenesis, may not be resolved.
The ideal approach would be to conditionally induce the
translocation in the synovial sarcoma cell of origin so as
to be able to follow the early events that most likely play
a crucial role in transformation and establishment of syn-
ovial sarcoma features.
The mechanisms that ensure SS18-SSX-associated chro-
matin remodelling complex recruitment to DNA require
further investigation. ATF2 and Tcf4/Lef provide concep-
tually attractive transcription factors to recruit SS18-SSX
to relevant regulatory regions but if they indeed do so, it is
likely that other transcription factors, some of which dis-
play pioneer functions, participate in SS18-SSX recruit-
ment to promoter and enhancer regions. It will then be es-
sential to determine the repertoire of transcription factors
that display such capability. Conversely, it is possible that
SS18-SSX is not recruited by transcription factors but
rather by other mechanisms that may include a combina-
tion of chromatin marks. In association with chromatin re-
modelling complexes, SS18-SSX may then merely open
chromatin in a manner that allows diverse transcription
factors to activate target genes whose concerted action
transforms target cells.
Another intriguing issue is the relative contribution of
HDAC and TLE1. Both display repressor functions and
our own results suggest that both are inactivated by
SS18-SSX. The relative contribution of BAF, HDAC,
TLE, PcG and other putative regulators of gene expression
needs to be better understood to obtain clear insight into
how SS18-SSX transforms target cells along with clues to-
ward designing effective mechanism-based therapeutic op-
tions.
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